Hospital Virgen De Los Lirios

The site is focused on oncology studies, with a strong emphasis on breast cancer and other neoplasms. Current trials are exploring new treatment combinations, comparing therapies, and improving ways to monitor disease response in people with early and high-risk breast cancer.

• Studies in triple-negative breast cancer are testing whether adding immunotherapy can improve event-free survival.
• Research in HER2-negative and HR-positive breast cancer is evaluating how well ctDNA can track minimal residual disease and treatment benefit.
• Trials in HER2-positive early breast cancer are assessing new neoadjuvant treatment combinations for patients with high-risk disease.

This program also includes work on invasive breast cancer and treatment effectiveness in patients at higher risk of relapse, reflecting a broader effort to refine cancer care at the Hospital Virgen De Los Lirios.

A major part of the research portfolio centers on breast cancer, especially early-stage disease and biologically defined subtypes such as HER2-negative, HR-positive, and triple-negative tumors. These studies aim to improve outcomes by testing better treatment strategies and identifying which patients are most likely to benefit.

• Evaluating whether adding immunotherapy to standard care can strengthen control of aggressive breast tumors.
• Comparing treatment approaches for early breast cancer to reduce the chance of recurrence.
• Using minimal residual disease markers to better understand how patients respond after initial therapy.

The overall goal is to support more personalized care for patients with early breast cancer, while improving survival and long-term disease control.

Within oncology, the site is also studying metastatic colorectal cancer, with attention to complications that can affect treatment safety and quality of life. One key area is prevention of venous thromboembolic disease in patients starting first-line systemic therapy.

• Assessing whether preventive treatment can lower the risk of VTE in people with advanced colorectal cancer.
• Supporting safer cancer care by reducing clot-related events during active treatment.
• Examining treatment effectiveness in a population with stage IV colon or rectal adenocarcinoma.

This line of research addresses both cancer control and the prevention of serious treatment-related complications in patients treated at Hospital Virgen De Los Lirios.

Another important theme is the use of ctDNA and other biomarkers to guide care in breast cancer. These studies are designed to improve how residual disease is detected and how treatment effectiveness is measured after initial therapy.

• Tracking ctDNA changes to identify early signs of response or persistent disease.
• Comparing different treatment arms to see which approach better reduces relapse risk.
• Helping clinicians refine follow-up strategies for patients with high-risk early breast cancer.

This research supports a more precise approach to cancer management, with the aim of matching treatment intensity to individual risk.